Compare BAK & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAK | CDNA |
|---|---|---|
| Founded | 1972 | 1998 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | BAK | CDNA |
|---|---|---|
| Price | $3.10 | $20.13 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.40 | ★ $26.67 |
| AVG Volume (30 Days) | ★ 1.1M | 751.3K |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | ★ $13,841,708,237.00 | $357,998,000.00 |
| Revenue This Year | N/A | $14.47 |
| Revenue Next Year | $7.81 | $11.35 |
| P/E Ratio | ★ N/A | $16.47 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $2.32 | $10.96 |
| 52 Week High | $5.10 | $25.55 |
| Indicator | BAK | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.60 | 55.38 |
| Support Level | $3.05 | $16.94 |
| Resistance Level | $3.37 | $21.20 |
| Average True Range (ATR) | 0.13 | 1.07 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 51.38 | 71.21 |
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.